Your browser doesn't support javascript.
loading
Hepatitis B Virus Targets Lipid Transport Pathways to Infect Hepatocytes.
Esser, Knud; Cheng, Xiaoming; Wettengel, Jochen M; Lucifora, Julie; Hansen-Palmus, Lea; Austen, Katharina; Roca Suarez, Armando A; Heintz, Sarah; Testoni, Barbara; Nebioglu, Firat; Pham, Minh Tu; Yang, Shangqing; Zernecke, Alma; Wohlleber, Dirk; Ringelhan, Marc; Broxtermann, Mathias; Hartmann, Daniel; Hüser, Norbert; Mergner, Julia; Pichlmair, Andreas; Thasler, Wolfgang E; Heikenwalder, Mathias; Gasteiger, Georg; Blutke, Andreas; Walch, Axel; Knolle, Percy A; Bartenschlager, Ralf; Protzer, Ulrike.
Afiliação
  • Esser K; Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany. Electronic address: knud.esser@tum.de.
  • Cheng X; Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany.
  • Wettengel JM; Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany.
  • Lucifora J; INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Lyon, and University of Lyon, Université Claude-Bernard (UCBL), Lyon, France; CIRI-Centre International de Recherche en Infectiologie, Inserm, U1111, University of Lyon, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS Lyon, Fra
  • Hansen-Palmus L; Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany.
  • Austen K; Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany.
  • Roca Suarez AA; CIRI-Centre International de Recherche en Infectiologie, Inserm, U1111, University of Lyon, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS Lyon, France.
  • Heintz S; CIRI-Centre International de Recherche en Infectiologie, Inserm, U1111, University of Lyon, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS Lyon, France.
  • Testoni B; CIRI-Centre International de Recherche en Infectiologie, Inserm, U1111, University of Lyon, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS Lyon, France.
  • Nebioglu F; Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Diseases Research, Heidelberg, Germany.
  • Pham MT; Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Diseases Research, Heidelberg, Germany.
  • Yang S; Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Diseases Research, Heidelberg, Germany.
  • Zernecke A; Institute of Experimental Biomedicine, University Hospital Würzburg, Würzburg, Germany.
  • Wohlleber D; Institute of Molecular Immunology and Experimental Oncology, University Hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany; German Center for Infection Research (DZIF), Munich and Heidelberg partner sites, Munich and Heidelberg, Germany.
  • Ringelhan M; German Center for Infection Research (DZIF), Munich and Heidelberg partner sites, Munich and Heidelberg, Germany; 2nd Medical Department, University Hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany.
  • Broxtermann M; Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany.
  • Hartmann D; Department of Surgery, University Hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany.
  • Hüser N; Department of Surgery, University Hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany.
  • Mergner J; Bavarian Center for Biomolecular Mass Spectrometry at Klinikum rechts der Isar (BayBioMS@MRI), TUM, Munich, Germany.
  • Pichlmair A; Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany; German Center for Infection Research (DZIF), Munich and Heidelberg partner sites, Munich and Heidelberg, Germany; Bavarian Center for Biomolecular Mass Spectrometry at Klinikum rechts der I
  • Thasler WE; Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Grosshadern Hospital, Ludwig Maximilians University, Munich, Germany.
  • Heikenwalder M; Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany.
  • Gasteiger G; Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany.
  • Blutke A; Institute of Pathology, Helmholtz Zentrum München, Neuherberg, Germany.
  • Walch A; Institute of Pathology, Helmholtz Zentrum München, Neuherberg, Germany.
  • Knolle PA; Institute of Molecular Immunology and Experimental Oncology, University Hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany; German Center for Infection Research (DZIF), Munich and Heidelberg partner sites, Munich and Heidelberg, Germany.
  • Bartenschlager R; Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Diseases Research, Heidelberg, Germany; German Center for Infection Research (DZIF), Munich and Heidelberg partner sites, Munich and Heidelberg, Germany; Divisi
  • Protzer U; Institute of Virology, Technical University of Munich, School of Medicine / Helmholtz Munich, Munich, Germany; German Center for Infection Research (DZIF), Munich and Heidelberg partner sites, Munich and Heidelberg, Germany. Electronic address: protzer@tum.de.
Cell Mol Gastroenterol Hepatol ; 16(2): 201-221, 2023.
Article em En | MEDLINE | ID: mdl-37054914
ABSTRACT
BACKGROUND &

AIMS:

A single hepatitis B virus (HBV) particle is sufficient to establish chronic infection of the liver after intravenous injection, suggesting that the virus targets hepatocytes via a highly efficient transport pathway. We therefore investigated whether HBV uses a physiological liver-directed pathway that supports specific host-cell targeting in vivo.

METHODS:

We established the ex vivo perfusion of intact human liver tissue that recapitulates the liver physiology to investigate HBV liver targeting. This model allowed us to investigate virus-host cell interactions in a cellular microenvironment mimicking the in vivo situation.

RESULTS:

HBV was rapidly sequestered by liver macrophages within 1 hour after a virus pulse perfusion but was detected in hepatocytes only after 16 hours. We found that HBV associates with lipoproteins in serum and within machrophages. Electron and immunofluorescence microscopy corroborated a co-localization in recycling endosomes within peripheral and liver macrophages. Recycling endosomes accumulated HBV and cholesterol, followed by transport of HBV back to the cell surface along the cholesterol efflux pathway. To reach hepatocytes as final target cells, HBV was able to utilize the hepatocyte-directed cholesterol transport machinery of macrophages.

CONCLUSIONS:

Our results propose that by binding to liver targeted lipoproteins and using the reverse cholesterol transport pathway of macrophages, HBV hijacks the physiological lipid transport pathways to the liver to most efficiently reach its target organ. This may involve transinfection of liver macrophages and result in deposition of HBV in the perisinusoidal space from where HBV can bind its receptor on hepatocytes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vírus da Hepatite B / Hepatite B Limite: Humans Idioma: En Revista: Cell Mol Gastroenterol Hepatol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vírus da Hepatite B / Hepatite B Limite: Humans Idioma: En Revista: Cell Mol Gastroenterol Hepatol Ano de publicação: 2023 Tipo de documento: Article
...